FDA Rejection Triggers Major Stock Collapse and Legal Action
Corcept Therapeutics ($CORT) faces a significant securities class action lawsuit following a devastating FDA decision that sent its stock plummeting nearly 50% in a single trading session. On December 31, 2025, the U.S. Food and Drug Administration issued a Complete Response Letter for relacorilant, the company's lead therapeutic candidate, citing insufficient evidence of effectiveness. The rejection triggered a sharp market reaction, with $CORT shares crashing from $70.20 to $34.80 in one day—a loss of approximately $35.40 per share or 50.4% of its value.
The lawsuit, announced by prominent plaintiff law firm Hagens Berman, alleges that Corcept Therapeutics concealed material information about FDA concerns while maintaining public confidence in the drug's approval prospects. According to the filing, investors who purchased $CORT shares between October 31, 2024 and December 30, 2025—the period during which the company allegedly misrepresented the regulatory outlook—have legal recourse. A critical deadline of April 21, 2026 marks the final opportunity for investors with substantial losses to become lead plaintiffs in the class action.
The Regulatory Setback and Timeline of Events
Relacorilant represented a cornerstone of Corcept Therapeutics' pipeline and commercial strategy. The medication is designed to treat Cushing syndrome, a rare endocrine disorder caused by excessive cortisol production. The FDA's decision to issue a Complete Response Letter rather than approval represents a significant regulatory hurdle, as such letters typically indicate that the agency cannot approve a drug in its current form and requires additional data or modifications.
The timing of the FDA's decision—arriving on the final day of 2025—compounded market shock. The pharmaceutical sector has faced heightened scrutiny around clinical trial design and efficacy standards in recent years, particularly for specialty drugs targeting rare diseases. The FDA's determination that relacorilant lacked "sufficient evidence of effectiveness" suggests that Corcept's clinical trial data did not meet the agency's statistical or clinical significance thresholds.
Key dates relevant to investor claims:
- October 31, 2024: Class period begins
- December 31, 2025: FDA issues Complete Response Letter
- December 30, 2025: Class period ends
- April 21, 2026: Deadline to become lead plaintiff
Market Context: Biotech Volatility and FDA Decision Risk
The $CORT collapse underscores the inherent risks in clinical-stage and late-stage biotech investments, where regulatory approval serves as a critical inflection point. Specialty pharmaceutical companies—particularly those dependent on a single or limited number of products—face elevated volatility when facing FDA decisions. A 50% single-day decline is not unprecedented in biotech, but it remains stark evidence of how much market value is typically embedded in approval expectations.
Corcept Therapeutics operates in the rare disease space, where development timelines are long, patient populations are small, and regulatory pathways can be unpredictable. The company's reliance on relacorilant for near-term revenue growth and clinical validation made the FDA rejection particularly damaging to shareholder value. The alleged concealment of FDA concerns—if substantiated in litigation—suggests that management may have known about regulatory obstacles while public statements remained optimistic.
This case joins a growing pattern of securities litigation in the biotech sector, where disclosure failures related to clinical trial results or regulatory communications have become common litigation targets. Investors in biotech firms have increasingly pursued legal remedies when material information about drug development challenges was allegedly withheld or misrepresented during critical periods.
Investor Implications and Shareholder Remedies
For investors who purchased $CORT during the identified class period, the lawsuit provides a potential avenue for recovery of losses. Securities class actions typically operate on a contingency basis, with law firms funding litigation in exchange for a percentage of any settlement or judgment. The strength of Hagens Berman's case depends on establishing several legal elements:
- Materiality: Did Corcept fail to disclose material facts about FDA concerns?
- Scienter: Did management act with intent to deceive or reckless disregard for truth?
- Reliance: Did investors rely on misleading statements when making purchase decisions?
- Causation: Did the FDA decision directly cause the stock price decline?
- Damages: Can losses be quantified and traced to the alleged misconduct?
The appointment of lead plaintiffs—shareholders with the largest documented losses—is crucial for class action efficiency and credibility. These individuals or institutional investors will oversee the litigation alongside counsel and must be certified by the court as representative of the broader shareholder class.
From a market perspective, $CORT's collapse raises questions about institutional investor diligence and sell-side analyst coverage. If warnings about relacorilant's regulatory pathway were knowable from public FDA guidance, pre-approval communications, or clinical trial designs, investors may scrutinize why such risks weren't more prominently flagged. Conversely, if Corcept management actively misled markets about the strength of its regulatory standing, the company faces both litigation exposure and reputational damage that could impair future capital-raising efforts.
Forward Outlook and Broader Industry Implications
The $CORT litigation will likely influence how biotech companies communicate with investors about FDA interactions and clinical trial expectations. Regulatory bodies have become increasingly focused on ensuring that public companies accurately represent the status and prospects of pipeline programs. The FDA's own guidance documents and pre-approval meeting notes are increasingly scrutinized in litigation to determine what companies knew and when they knew it.
For the broader biotech sector, this case serves as a reminder that regulatory risk is not always adequately priced into stock valuations, particularly for companies with limited product diversification. Investors and analysts may place greater emphasis on obtaining granular clinical trial data, understanding FDA feedback mechanisms, and assessing management's track record of candor regarding development setbacks.
Corcept Therapeutics now faces a multi-front challenge: managing the commercial and clinical implications of the FDA rejection, potentially pursuing resubmission or product modification pathways, and defending against shareholder litigation. The company's response to this setback—whether through accelerated development of alternative formulations, strategic partnerships, or portfolio diversification—will significantly influence its long-term viability and investor confidence.
The April 21, 2026 lead plaintiff deadline represents a concrete checkpoint for affected shareholders to take action. Given the magnitude of losses demonstrated in a single-day decline from $70.20 to $34.80, eligible investors should carefully review their transaction records and consider consulting with securities counsel to assess claim eligibility and potential recovery prospects.